Original Research
Accepted on 24 Oct 2025
Adjuvant tyrosine kinase inhibitors plus anti‑PD‑1 therapy reduce recurrence in high-risk hepatocellular carcinoma after resection
in Cancer Immunity and Immunotherapy
Original Research
Accepted on 24 Oct 2025
in Cancer Immunity and Immunotherapy
Original Research
Accepted on 24 Oct 2025
in Thoracic Oncology
Case Report
Accepted on 24 Oct 2025
in Radiation Oncology
Systematic Review
Accepted on 24 Oct 2025
in Breast Cancer
Review
Accepted on 24 Oct 2025
in Cancer Imaging and Image-directed Interventions
Original Research
Accepted on 24 Oct 2025
in Breast Cancer
Original Research
Accepted on 24 Oct 2025
in Head and Neck Cancer
Original Research
Accepted on 24 Oct 2025
in Head and Neck Cancer
Original Research
Accepted on 24 Oct 2025
in Gastrointestinal Cancers: Colorectal Cancer
Original Research
Accepted on 24 Oct 2025
in Gastrointestinal Cancers: Colorectal Cancer
Original Research
Accepted on 24 Oct 2025
in Pediatric Oncology
Case Report
Accepted on 24 Oct 2025
in Surgical Oncology
Original Research
Accepted on 24 Oct 2025
in Genitourinary Oncology
Original Research
Accepted on 24 Oct 2025
in Hematologic Malignancies
Case Report
Accepted on 24 Oct 2025
in Neuro-Oncology and Neurosurgical Oncology
Original Research
Accepted on 24 Oct 2025
in Head and Neck Cancer